British biologists have identified a molecule that assists the body in restraining persistent inflammation. This was reported by the press service of University College London (UCL). The discovery might form the basis for novel therapeutic approaches, such as for rheumatoid arthritis.
Researchers ascertained that a molecule from the epoxy-oxylipin class—epoxidized linoleic acid—plays a central role. It slows down the generation of pathogenic immune cells known as monocytes, which cause tissue damage.
“We have uncovered an already existing chain of signals in the body that curtails the proliferation of potentially harmful immune cells and helps subdue inflammation through a speedier route. If we learn to control this mechanism, it will enable us to devise more potent and safer means of restoring immune system equilibrium without completely suppressing it,” stated UCL research fellow Olivia Bracken.
During the experiment, volunteers were induced to have an inflammatory response. Some were administered the drug GSK2256294, which inhibits the SEH enzyme that breaks down beneficial epoxy-oxylipins. This alleviated the inflammation and pain. Scientists believe that therapy based on this principle could slow down joint destruction in arthritis.
About the Author
